MICROPORT NEURO(02172.HK): NUMEN™ Helia Coil Obtains FDA Marketing Approval

NewTimeSpace · 2026/05/25 18:22 · By Jiayi Sun

NewTimeSpace News: MicroPort NeuroScientific Corporation (02172.HK) announced that the NUMEN™ Helia Coil Embolization System, independently developed by its subsidiary MicroPort NeuroTech (Shanghai) Co., Ltd., has recently received marketing approval from the U.S. Food and Drug Administration (FDA). This marks the Group’s third coil product approved for marketing in the U.S., following the NUMEN™ Detachable Coil and NUMEN™ Silk 3D Electrolytic Detachable Coil.

NewTimeSpace News: MicroPort NeuroScientific Corporation (02172.HK) issued a voluntary announcement on May 25, 2026, disclosing that the NUMEN™ Helia Coil has obtained FDA marketing approval.
NUMEN™ Helia is indicated for the endovascular occlusion or obstruction of neurovascular abnormalities to interrupt blood flow. Compared with the marketed NUMEN™ series coils, NUMEN™ Helia features "longer, thinner, softer" and is compatible with 0.013-inch microcatheters. It meets the delivery and embolization needs in small, tortuous, or access-restricted vessels, providing a more refined solution for complex vascular lesions.
Core Design Advantages，Adopts a unique Cube/Spiral configuration to enhance anchoring on the vessel wall;Diameter ranges from 1 mm to 3.5 mm, with a maximum length of 60 cm and multiple ultra-long specifications available;Ultra-soft coil body design, suitable for delivery in small vessels and complex paths.
This approval further optimizes the Group’s product portfolio in the North American neurointerventional embolization field, demonstrating sustained breakthroughs in innovative neurointerventional product R&D and international registration. The Group will accelerate global registration and commercialization of innovative products, continuing to refine integrated neurointerventional solutions.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

MICROPORT NEURO 02172.HK FDA